ENTVAC Consortium Phase II

Project Department: Uni Research Environment (group: Applied Biotechnology) period: 04.10.16 - 03.10.18

Project results

Taxt AM, Diaz Y, Aasland R, Clements JD, Nataro JP, Sommerfelt H, Puntervoll P. (2016) Towards Rational Design of a Toxoid Vaccine against the Heat-Stable Toxin of Escherichia coli. Infect Immun. 24;84(4):1239-1249.

Taxt AM, Diaz Y, Bacle A, Grauffel C, Reuter N, Aasland R, Sommerfelt H, Puntervoll P. (2014) Characterization of immunological cross-reactivity between enterotoxigenic Escherichia coli heat-stable toxin and human guanylin and uroguanylin. Infect Immun. 82(7):2913-2922.

About the project

Developing a vaccine for protection against diarrhea caused by ST-producing ETEC

Enterotoxigenic E. coli (ETEC) expressing the heat-stable toxin (ST) is among the most important causes of diarrheal disease in children less than 5 years of age in low- and middle-income countries. Diarrhea causes ill health and malnutrition, and is the second most common cause of death among children. Currently available prototype ETEC vaccines target colonization factors and the heat-labile toxin, but not ST. They have so far failed to confer adequate protection, and development of an ST-based vaccine has a high priority.

The project owner is University of Maryland, and the partner institutions are University of Bergen, Tulane University, Kansas State University, and University of Virginia. 

The project is funded by PATH through the Enteric Vaccine Initiative, and the consortium has received funding from PATH since 2010.

cp: 2017-12-14 04:16:26